Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Cancers (Basel)
2017 Aug 12;98:. doi: 10.3390/cancers9080106.
Show Gene links
Show Anatomy links
ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients.
Hofman P
.
???displayArticle.abstract???
Patients with advanced stage non-small cell lung carcinoma (NSCLC) harboring an anaplastic lymphoma kinase ALK gene rearrangement, detected from a tissue sample, can benefit from targeted ALK inhibitor treatment. However, while treatment is initially effective in most cases, relapse or progression occurs due to different resistance mechanisms including mutations in the tyrosine kinase domain of echinoderm microtubule-associated protein-like 4 (EML44)-ALK. The liquid biopsy concept has recently radically changed the clinical care of NSCLC patients, in particular for those harboring an epidermal growth factor receptor (EGFR) gene mutation. Therefore, liquid biopsy is an alternative or complementary method to tissue biopsy for the detection of some resistance mutations in EGFR arising during tyrosine kinase inhibitor treatment. Moreover, in some frail patients, or if the tumor lesion is not accessible to a tissue biopsy, a liquid biopsy can also detect some activating mutations in EGFR on initial assessment. Recent studies have evaluated the possibility of also using a liquid biopsy approach to detect an ALK rearrangement and/or the emergence during inhibitor treatment of some resistance mutations in ALK. These assessments can be performed by studying circulating tumor cells by fluorescent in situ hybridization and by immunocytochemistry and/or after the isolation of RNA from plasma samples, free or associated with platelets. Thus, the liquid biopsy may be a complementary or sometimes alternative method for the assessment of the ALK status in certain NSCLC patients, as well as a non-invasive approach for early detection of ALK mutations. In this review, we highlight the current data concerning the role of the liquid biopsy for the ALK status assessment for NSCLC patients, and we compare the different approaches for this evaluation from blood samples.
Abbosh,
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
2017,
Pubmed
Abel,
Detection of gene rearrangements in targeted clinical next-generation sequencing.
2014,
Pubmed
Aieta,
Monitoring and Characterization of Circulating Tumor Cells (CTCs) in a Patient With EML4-ALK-Positive Non-Small Cell Lung Cancer (NSCLC).
2016,
Pubmed
Ali,
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
2016,
Pubmed
Alix-Panabières,
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
2016,
Pubmed
Alix-Panabières,
Technologies for detection of circulating tumor cells: facts and vision.
2014,
Pubmed
Barlesi,
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
2016,
Pubmed
Bernabé,
What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?
2017,
Pubmed
Best,
RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics.
2015,
Pubmed
Betz,
The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma.
2013,
Pubmed
Chu,
Liquid biopsy: unlocking the potentials of cell-free DNA.
2017,
Pubmed
Cui,
Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer.
2017,
Pubmed
Dagogo-Jack,
Crizotinib resistance: implications for therapeutic strategies.
2016,
Pubmed
Dagogo-Jack,
Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas.
2017,
Pubmed
Dagogo-Jack,
Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?
2016,
Pubmed
Faugeroux,
Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer.
2014,
Pubmed
Gainor,
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
2016,
Pubmed
Hofman,
Pathologists and liquid biopsies: to be or not to be?
2016,
Pubmed
Hofman,
Liquid biopsy for early detection of lung cancer.
2017,
Pubmed
Hofman,
Detection of circulating tumor cells from lung cancer patients in the era of targeted therapy: promises, drawbacks and pitfalls.
2014,
Pubmed
Hofman,
Morphological analysis of circulating tumour cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method.
2012,
Pubmed
Ilie,
Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?
2014,
Pubmed
Ilie,
ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma.
2012,
Pubmed
Ilié,
Pros: Can tissue biopsy be replaced by liquid biopsy?
2016,
Pubmed
Kerr,
Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?
2016,
Pubmed
Le,
ALK alterations and inhibition in lung cancer.
2017,
Pubmed
Li,
Circulating microRNAs as novel biomarkers of ALK-positive nonsmall cell lung cancer and predictors of response to crizotinib therapy.
2017,
Pubmed
Lin,
Targeting ALK: Precision Medicine Takes on Drug Resistance.
2017,
Pubmed
Long-Mira,
Sense and nonsense in the process of accreditation of a pathology laboratory.
2016,
Pubmed
Minca,
ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material.
2014,
Pubmed
Newman,
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.
2014,
Pubmed
Nilsson,
Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.
2016,
Pubmed
Nilsson,
Blood platelets contain tumor-derived RNA biomarkers.
2011,
Pubmed
Pailler,
Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.
2013,
Pubmed
Pailler,
Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.
2017,
Pubmed
Perkins,
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers.
2012,
Pubmed
Peters,
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
2017,
Pubmed
Proietti,
Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
2014,
Pubmed
Sacher,
Application of Plasma Genotyping Technologies in Non-Small Cell Lung Cancer: A Practical Review.
2017,
Pubmed
Sakai,
Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor.
2013,
Pubmed
Schwaederlé,
Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma.
2017,
Pubmed
Siravegna,
Integrating liquid biopsies into the management of cancer.
2017,
Pubmed
Siravegna,
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor.
2017,
Pubmed
Tan,
Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer.
2016,
Pubmed
Wang,
Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma.
2017,
Pubmed
Washetine,
[The accreditation of a surgical pathology and somatic genetic laboratory (LPCE, CHU of Nice) according to the ISO 15189 norm: Sharing of experience].
2013,
Pubmed
Yatabe,
ALK FISH and IHC: you cannot have one without the other.
2015,
Pubmed
Zhong,
Malignant pleural effusion cell blocks are substitutes for tissue in EML4-ALK rearrangement detection in patients with advanced non-small-cell lung cancer.
2016,
Pubmed
Zito Marino,
Diagnosis of anaplastic lymphoma kinase rearrangement in cytological samples through a fluorescence in situ hybridization-based assay: Cytological smears versus cell blocks.
2017,
Pubmed